



DAFTAR PUSTAKA

- [1] IARC, “Cancer Today,” *Cancer Today*, 2020. https://gco.iarc.fr/today/online-analysis-map?v=2020&mode=population&mode_population=continents&population=900&populations=900&key=crude_rate&sex=2&cancer=23&type=1&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_item (accessed Feb. 26, 2021).
- [2] S. Pangribowo, “Beban Kanker di Indonesia,” *Pus. Data dan Inf. Kementeri. Kesehat. RI*, pp. 1–16, 2019.
- [3] Kemenkes RI, “Hari Kanker Sedunia 2019,” *Kementerian Kesehatan RI*, 2019. <https://www.kemkes.go.id/article/view/20012900002/Kesiapsiagaan-menghadapi-Infeksi-Novel-Coronavirus.html%0Ahttps://www.depkes.go.id/article/view/19020100003/hari-kanker-sedunia-2019.html> (accessed Mar. 03, 2021).
- [4] Kemenkes RI, “Penanggulangan Kanker Payudara dan Kanker Leher Rahim,” 2015.
- [5] A. Wambersie, F. Richard, and N. Breteau, “Development of Fast Neutron Therapy Worldwide: Radiobiological ,Clinical and Technical Aspects,” *Acta Ontol.*, vol. 33, no. 3, pp. 261–274, 1994, doi: 10.3109/02841869409098416.
- [6] S. Morita *et al.*, “Clinical Experience of Fast Neutron Therapy for Carcinoma of The Uterine Cervix,” *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 11, pp. 1439–1445, 1985.
- [7] M. H. Maor *et al.*, “Therapy in Cervical Cancer: Results of A Phase III RTOG Study,” *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 14, pp. 885–891, 1988.
- [8] T. Sato *et al.*, “Overview of Particle and Heavy Ion Transport Code System PHITS,” *Ann. Nucl. Energy*, 2014, doi: 10.1016/j.anucene.2014.08.023.
- [9] T. W. Griffin, G. E. Laramore, D. H. Husey, F. R. Hendrickson, and A. Rodriguez-Antunez, “Fast Neutron Beam Radiation Therapy in The United States,” *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 8, no. 12, pp. 2165–2168, 1982.
- [10] K. L. Lindsley *et al.*, “Clinical Trials of Neutron Radiotherapy in The United States,” *Bull. du Cancer/Radiotherapie*, vol. 83, no. Suppl 1, pp. 78s-86s, 1996, doi: 10.1016/0924-4212(96)84889-4.
- [11] T. Egawa-takata, P. K. Yoshino, and K. Hiramatsu, “Small Cell Carcinomas of the Uterine Cervix and Lung Proteomics Reveals Similar Protein Expression Profiles,” vol. 28, no. 9, pp. 1751–1757, 2018, doi: 10.1097/IGC.0000000000001354.





- [12] International Commission on Radiological Protection, “ICRP Publication 118: Early and Late Effects of Radiation in Normal Tissues and Organs – Threshold Doses for Tissue Reactions in A Radiation Protection Context,” *Ann. ICRP*, vol. 41, no. 1–2, pp. 37–309, 2012.
- [13] Kemenkes RI, Nasional, and Komite Penanggulangan Kanker, “Panduan Penatalaksanaan Kanker Serviks.”
- [14] Kemenkes RI, “Pedoman Nasional Pelayanan Kedokteran Kanker Serviks,” 2017. doi: 10.1111/j.1467-6435.1975.tb01941.x.
- [15] J. Zhang, L. Bian, and H. Liu, “CD44+/CD24+ -Expressing Cervical Cancer Cells and Radioresistant Cervical Cancer Cells Exhibit Cancer Stem Cell Characteristics,” *Gynecol. Obstet. Invest.*, pp. 1–9, 2018, doi: 10.1159/000493129.
- [16] T. H. Leung *et al.*, “HPV-E6 Protein Enriches The CD55+ Population in Cervical Cancer Cells Promoting Radio-Resistance and Cancer Aggressiveness,” *J. Pathol.*, vol. 244, no. 2, pp. 151–163, 2018.
- [17] C. A. Kunos and S. P. Ivy, “Triapine Radiochemotherapy in Advanced Stage Cervical Cancer,” *Front. Oncol.*, vol. 8, no. 149, pp. 1–7, 2018, doi: 10.3389/fonc.2018.00149.
- [18] N. Chaudary, M. Pintilie, S. Jelveh, P. Lindsay, R. P. Hill, and M. Milosevic, “Plerixafor Improves Primary Tumor Response and Reduces Metastases in Cervical Cancer Treated with Radio-Chemotherapy,” *Clin. Cancer Res.*, vol. 23, no. 5, pp. 1242–1249, 2017.
- [19] J. L. Li, X. X. Wang, H. J. Hu, and X. Bin Xu, “FEN1 Inhibitor Increases Sensitivity of Radiotherapy in Cervical Cancer Cells,” *Cancer Med.*, pp. 1–7, 2019, doi: 10.1002/cam4.2615.
- [20] G. B. Moffitt *et al.*, “Dosimetric Characteristics of The University of Washington Clinical Neutron Therapy System,” *Phys. Med. Biol.*, 2018.
- [21] W. Megasari and UGM, “Analisis Dosis Radiasi Terapi Kanker Berbasis Fast Neutron Therapy (FNT) dan Boron Neutron Capture Therapy (BNCT) Menggunakan Program Particle and Heavy Ion Transport Code System (PHITS),” Universitas Gadjah Mada, 2020.
- [22] “ICRU Report 45: Clinical Neutron Dosimetry Part I: Determination of Absorbed Dose in A Patient Treated by External Beams of Fast Neutrons,” *Radiat. Res.*, 1989.
- [23] D. Krstic and D. Nikezic, “Input Files with ORNL — Mathematical Phantoms of The Human Body for MCNP-4B,” *Comput. Phys. Commun.*, vol. 176, pp. 33–37, 2007, doi: 10.1016/j.cpc.2006.06.016.
- [24] K. F. Eckerman, *Development of PIMAL: Mathematical Phantom with Moving Arms and Legs*, no. May. 2007.





- [25] A. G. Boham, S. Trihandaru, and A. Setiawan, “Simulasi Komputasi Lokasi dan Orientasi Kanker pada ORNL-MIRD,” *Univ. Res. Colloq.*, vol. 11, pp. 173–182, 2020.
- [26] E. Y. Han, K. F. Eckerman, and W. E. Bolch, “Revision to The ORNL Series of Adult and Pediatric Computational Phantoms for Use with The MIRD Schema,” *Health Phys.*, 2006, doi: 10.1097/01.HP.0000192318.13190.c4.
- [27] P. Hartono, “Kanker Serviks.”
- [28] “Kanker Serviks Stadium 1, Ini yang Terjadi pada Tubuh Anda.” <https://hellosehat.com/kanker/kanker-serviks/stadium-kanker-serviks/> (accessed May 21, 2021).
- [29] “Stage 3 | Cervical cancer | Cancer Research UK.” <https://www.cancerresearchuk.org/about-cancer/cervical-cancer/stages-types-grades/stage-3> (accessed May 21, 2021).
- [30] V. M. Golovkov and A. M. Shehada, “Improving Neutron Flux by Optimizing The Geometries and Materials of The Collimation Assembly for Fast Neutron Therapy,” vol. 2, pp. 44–50, 2019.
- [31] G. B. Moffitt *et al.*, “Scattering Kernels for Fast Neutron Therapy Treatment Planning,” *Phys. Med. Biol.*, 2020, doi: 10.1016/j.snb.2007.07.003.
- [32] G. B. Moffitt, R. D. Stewart, G. A. Sandison, J. T. Goorley, D. C. Argento, and T. Jevremovic, “MCNP6 Model of The University of Washington Clinical Neutron Therapy System (CANTS),” *Phys. Med. Biol.*, vol. 61, pp. 937–957, 2016, doi: 10.1088/0031-9155/61/2/937.
- [33] M. B. Chadwick *et al.*, “Nuclear Data For Fast Neutron and Proton Therapy,” pp. 23–35.
- [34] R. W. Schulte, “ICRU Report 63: Nuclear Data for Neutron and Proton Radiotherapy and for Radiation Protection,” *Radiat. Res.*, vol. 156, no. 2, pp. 223–224, 2001, doi: 10.1667/0033-7587(2001)156[0223:]2.0.co;2.
- [35] R. L. Maughan, P. J. Chuba, A. T. Porter, E. Ben-josef, and D. R. Lucas, “The Elemental Composition of Tumors: Kerma Data for Neutrons,” *Med. Phys.*, vol. 24, no. 8, pp. 1241–1244, 1997, doi: 10.1118/1.598144.
- [36] “ICRU Report 46: Photon, Electron, Proton, and Neutron Interaction Data for Body Tissues,” *Radiat. Res.*, 1991.
- [37] M. Schiffman, P. E. Castle, J. Jeronimo, A. C. Rodriguez, and S. Wacholder, “Human Papillomavirus and Cervical Cancer,” in *The Lancet*, 2007, vol. 370, pp. 890–907, doi: 10.1007/s00340-014-5843-9.
- [38] T. A. Berman and J. T. Schiller, “Human Papillomavirus in Cervical Cancer and Oropharyngeal Cancer: One Cause, Two Diseases,” *Cancer*, vol. 123, no. 12, pp. 2219–2229, 2017, doi: 10.1002/cncr.30588.





- [39] N. Bhatla *et al.*, “Revised FIGO Staging for Carcinoma of The Cervix Uteri,” *Int. J. Gynecol. Obstet.*, vol. 145, no. 1, pp. 129–135, 2019, doi: 10.1002/ijgo.12749.
- [40] N. Tsoulfanidis and S. Landsberger, *Measurement and Detection of Radiation*, 4th ed. Taylor & Francis Group, 2015.
- [41] E. B. Podgorsak, *Radiation Oncology Physics: A Handbook for Teachers and Students*. 2005.
- [42] Kemenkes RI, “Peraturan Menteri Kesehatan Republik Indonesia Nomor 780/MENKES/PER/VIII/2008 Tentang Penyelenggaraan Pelayanan Radiologi,” 2008.
- [43] Kepala BAPETEN RI, “Peraturan Kepala Badan Pengawas Tenaga Nuklir Nomor 3 Tahun 2013 Tentang Keselamatan Radiasi Dalam Penggunaan Radioterapi,” 2013.
- [44] W. J. Koh *et al.*, “Cervical Cancer, Version 3.2019,” *JNCCN J. Natl. Compr. Cancer Netw.*, vol. 17, no. 1, pp. 64–84, 2019, doi: 10.6004/jnccn.2019.0001.
- [45] E. B. Podgorsak, *Radiation Physics for Medical Physicists*. 2010.
- [46] L. Wootton, “Toward Intensity Modulated Treatment on The University of Washington Clinical Neutron Therapy System CNTS History at University of Washington,” Austin, 2018.
- [47] D. L. Schwartz, J. Einck, J. Bellon, and G. E. Laramore, “Fast Neutron Radiotherapy for Soft Tissue and Cartilaginous Sarcomas at High Risk for Local Recurrence,” *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 50, no. 2, pp. 449–456, 2001, doi: 10.1016/S0360-3016(00)01586-8.
- [48] J. Soderberg, *Dosimetry and Radiation Quality in Fast-Neutron Radiation Therapy*, no. 989. 2007.
- [49] J. G. Douglas, W. J. Koh, M. Austin-Seymour, and G. E. Laramore, “Treatment of Salivary Gland Neoplasms with Fast Neutron Radiotherapy,” *Arch. Otolaryngol. - Head Neck Surg.*, vol. 129, no. 9, pp. 944–948, 2003, doi: 10.1001/archotol.129.9.944.
- [50] A. M. Kalet, G. A. Sandison, M. H. Phillips, and U. Parvathaneni, “Validation of The Pinnacle3 Photon Convolution-Superposition Algorithm Applied to Fast Neutron Beams,” *J. Appl. Clin. Med. Phys.*, vol. 14, no. 6, pp. 133–154, 2013, doi: 10.1120/jacmp.v14i6.4305.
- [51] Wikiwand, “Fast Neutron Therapy.” https://www.wikiwand.com/en/Fast_neutron_therapy (accessed Nov. 14, 2021).
- [52] G. Iliakis, E. Mladenov, and V. Mladenova, “Necessities in The Processing of DNA Double Strand Breaks and Their Effects on Genomic Instability and Cancer,” *Cancers (Basel.)*, vol. 11, no. 11, 2019, doi:





10.3390/cancers11111671.

- [53] T. W. Griffin *et al.*, “Neutron vs Photon Irradiation of Inoperable Salivary Gland Tumors: Results of An RTOG-MRC Cooperative Randomized Study,” *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 15, no. 5, pp. 1085–1090, 1988, doi: 10.1016/0360-3016(88)90188-5.
- [54] D. Kubik, “Clinical Neutron Therapy Center,” 2005.
- [55] D. Pang, B. L. Berman, S. Chasovskikh, J. E. Rodgers, and A. Dritschilo, “Investigation of Neutron-Induced Damage in DNA by Atomic Force Microscopy: Experimental Evidence of Clustered DNA Lesions,” *Radiat. Res.*, vol. 150, no. 6, pp. 612–618, 1998.
- [56] G. E. Laramore *et al.*, “Neutron Versus Photon Irradiation for Unresectable Salivary Gland Tumors: Final Report of An RTOG-MRC Randomized Clinical Trial,” *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 27, no. 2, pp. 235–240, 1993, doi: 10.1016/0360-3016(93)90233-L.
- [57] J. A. N. J. Battermann, K. Breur, G. A. M. Hart, and H. A. V. A. N. Peperzeel, “Observations on Pulmonary Metastases in Patients After Single Doses and Multiple Fractions of Fast Neutrons and Cobalt-60 Gamma Rays,” vol. 17, no. 5, pp. 539–548, 1981.
- [58] M. W. Macomber *et al.*, “Neutron Radiation Therapy for Treatment of Refractory Merkel Cell Carcinoma,” *Int. J. Part. Ther.*, vol. 3, no. 4, pp. 485–491, 2017, doi: 10.14338/ijpt-17-00003.1.
- [59] F. M. Wagner, B. Loeper-Kabasakal, and H. Breitkreutz, “Neutron Medical Treatment of Tumours - A Survey of Facilities,” *J. Instrum.*, vol. 7, no. 3, 2012, doi: 10.1088/1748-0221/7/03/C03041.
- [60] I. M. Ardana and Y. Sardjono, “Optimization of A Neutron Beam Shaping Assembly Design for BNCT and Its Dosimetry Simulation Based on MCNPX,” *J. Teknol. Reakt. Nukl. Tri Dasa Mega*, vol. 19, no. 3, p. 121, 2017, doi: 10.17146/tdm.2017.19.3.3582.
- [61] A. Wambersie and H. G. Menzel, “Present Status, Trends and Needs in Fast Neutron Therapy,” *Bull. du Cancer/Radiotherapie*, vol. 83, no. SUPPL. 1, pp. 68s–77s, 1996, doi: 10.1016/0924-4212(96)84888-2.
- [62] IAEA, “Nuclear Data for Neutron Therapy: Status and Future needs,” *IAEA TECDOC 992*, pp. 1–122, 1997, [Online]. Available: <http://www-pub.iaea.org/books/IAEABooks/5647/Nuclear-Data-for-Neutron-Therapy-Status-and-Future-Needs>.
- [63] K. Niita, H. Takada, S. Meigo, and Y. Ikeda, “High Energy Particle Transport Code NMTC/JAM,” in *ICANS-XV 15th Meeting of the International Collaboration on Advanced Neutron Sources*, 2001, pp. 964–970.





- [64] T. Itoga *et al.*, “Measurements of Differential Thick Target Neutron Yield for Fe, Cu (p , xn) Reactions at 35, 50, and 75 MeV,” 2003.
- [65] Tatsuhiko Sato et. al, *PHITS Ver. 3.22 User’s Manual* . .
- [66] K. T. Barnhart, A. Izquierdo, E. S. Pretorius, D. M. Shera, M. Shabbout, and A. Shaunik, “Baseline Dimensions of The Human Vagina,” *Hum. Reprod.*, vol. 21, no. 6, pp. 1618–1622, 2006, doi: 10.1093/humrep/del022.
- [67] R. J. Kurman, L. H. Ellenson, and B. M. Ronnett, *Blaustein’s Pathology of the Female Genital Tract*, vol. 82, no. 1. 2019.
- [68] M. S. Gunjotikar and K. S. J, “Ultrasonographic Study of Cervical Parameters in Primigravidas and Its Relation with Pregnancy Outcome,” *Orig. Res. Artic.*, vol. 4, no. 1, pp. 432–436, 2017, doi: 10.18231/2394-2754.2017.0097.
- [69] IARC group, “Chapter 1: An Introduction to The Anatomy of The Uterine Cervix,” 2015. [Online]. Available: <http://screening.iarc.fr/colpochap.php?lang=1&chap=1>.
- [70] W. Eppel, B. Schurz, P. Frigo, and E. Reinold, “Vaginosonographische Beobachtungen des zervikalen Verschlußapparates unter besonderer Berücksichtigung der Parität,” *Geburtshilfe Frauenheilkd.*, vol. 52, no. 03, pp. 148–151, 1992, doi: 10.1055/s-2007-1026115.
- [71] C. Udhani and M. Refaey, “Uterus,” *Radiopaedia.org*, Sep. 2008, doi: 10.53347/RID-4570.
- [72] Britannica, “Anatomy & Physiology: Fallopian Tube.” <https://www.britannica.com/science/fallopian-tube> (accessed Oct. 30, 2021).
- [73] A. Khan and R. Khan, “Understanding Pelvic Ultrasound Reports,” *GPOne*, 2010. <https://www.gponline.com/understanding-pelvic-ultrasound-reports/article/1032736> (accessed Oct. 30, 2021).
- [74] Cancer Research UK, “Cervical Cancer: Stage 3.” <https://www.cancerresearchuk.org/about-cancer/cervical-cancer/stages-types-grades/stage-3> (accessed Oct. 30, 2021).
- [75] National Cancer Institute, “Definition of Stage III Cervical Cancer,” *NCI Dictionary of Cancer Terms*. <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/stage-iii-cervical-cancer> (accessed Oct. 30, 2021).
- [76] L. Gland, “Normal Tissue Constraint Guidelines,” pp. 567–570.
- [77] J. S. Stroud, D. Mutch, J. Rader, and M. Powell, “Effects of Cancer Treatment on Ovarian Function,” *Fertil. Steril.*, vol. 92, no. 2, pp. 417–427, 2010, doi: 10.1016/j.fertnstert.2008.07.1714.
- [78] R. Lohynska *et al.*, “Proposal for Radiotherapy Dose Constraint Predicting





Uterus Fertility Sparing: Successful Pregnancy Case Report after Curative Chemoradiotherapy for Rectal Cancer,” *Austin J. Cancer Clin. Res.*, vol. 7, no. 1, pp. 1–3, 2020.

- [79] International Commission on Radiological Protection, “ICRP Publication 103: The 2007 Recommendations of International Commision on Radiological Protection,” *Ann. ICRP*, 2007.
- [80] *Sobotta: Atlas of Human Anatomy Volume 2: Trunk, Viscera, Lower Limb*, vol. 2. 2006.
- [81] “Anatomy of the Uterus | Ovaries | 3D Anatomy Tutorial - YouTube.” <https://www.youtube.com/watch?v=J3oky60tXCC> (accessed Oct. 30, 2021).
- [82] D. E. Bonnett, J. R. Williams, and C. J. Parnell, “The Isocentric Fast Neutron Therapy Facility at Edinburgh,” *Brittish J. Radiol.*, vol. 53, pp. 12–20, 1980.
- [83] B. P. Offerman and M. R. Cleland, “AEG/RDI Neutron Therapy Unit,” *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 3, pp. 377–382, 1997.
- [84] IARC, “Glossary,” *Glossary of Terms*, 2010. <https://www-dep.iarc.fr/whodb/glossary.htm> (accessed Mar. 03, 2021).
- [85] L. T. Van Hulsteijn, E. P. M. Corssmit, I. E. M. Coremans, J. W. A. Smit, J. C. Jansen, and O. M. Dekkers, “Regression and Local Control Rates After Radiotherapy for Jugulotympanic Paragangliomas: Systematic Review and Meta-Analysis,” *Radiotherapy and Oncology*, vol. 106, no. 2. Elsevier, pp. 161–168, Feb. 01, 2013, doi: 10.1016/j.radonc.2012.11.002.
- [86] “Definition of Distant Metastasis - NCI Dictionary of Cancer Terms - National Cancer Institute.” <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/distant-metastasis> (accessed May 20, 2021).
- [87] “Fistula, Saluran Abnormal yang Terbentuk di Antara Organ Tubuh - Alodokter.” <https://www.alodokter.com/fistula-munculnya-saluran-antara-bagian-tubuh> (accessed May 21, 2021).
- [88] “7 Things Everyone Should Know about Pulmonary Fibrosis | American Lung Association.” <https://www.lung.org/blog/7-things-know-pulmonary-fibrosis> (accessed May 21, 2021).
- [89] J. K. C. Chan, C. S. Ngt, and P. K. Hui, “A Simple Guide to The Terminology and Application of Leucocyte Monoclonal Antibodies,” *Hispatology*, vol. 12, pp. 461–480, 1988.
- [90] R. Shanker, “A Quasi Exponential Distribution,” *Biometrics Biostat. Int. J.*, vol. 7, no. 2, pp. 90–94, 2018, doi: 10.15406/bbij.2018.07.00194.
- [91] C. F. Von Essen, “Radiation Tolerance of The Skin,” *Acta Oncol. (Madr.)*, vol. 8, no. 4, pp. 311–330, 1969, doi: 10.3109/02841866909134462.





- [92] M. Kumar, R. Thangaraj, R. C. Alva, K. Koushik, A. Ponni, and J. M. G. Achar, “Impact of Different Dose Prescription Schedules on EQD2 in High-Dose-Rate Intracavitary Brachytherapy of Carcinoma Cervix,” *J. Contemp. Brachytherapy*, vol. 11, no. 2, pp. 189–193, 2019, doi: 10.5114/jcb.2019.84586.
- [93] J. D. Cossairt and Fermi National Accelerator Laboratory, “Accelerator Physics for Health Physicists.”

